Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Quest Diagnostics Sells Drug Royalties

by Ann M. Thayer
July 29, 2013 | A version of this story appeared in Volume 91, Issue 30

Quest Diagnostics has sold the rights to royalties on future sales of the anticancer drug candidate ibrutinib to Royalty Pharma for $485 million. Quest got rights to royalties on several drug candidates via its 2011 purchase of Celera. Ibrutinib development partners Johnson & Johnson and Pharmacyclics have filed for approval of the compound, which FDA has designated a breakthrough therapy. Since November 2012, Quest has been refocusing on its core diagnostics business. It earlier sold a dental diagnostics company, OralDNA, and a point-of-care testing firm, HemoCue.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.